Description
The 22-19-12 monoclonal antibody specifically recognizes CXC chemokine ligand 16 (CXCL16) which is also known as C-X-C motif chemokine 16, Scavenger receptor for phosphatidylserine and oxidized low density lipoprotein (SR-PSOX), or Small-inducible cytokine B16 (SCYB16). CXCL16 is a ~30 kDa single-pass type I transmembrane glycoprotein with an extracellular CXC chemokine domain and mucin-like spacer region, followed by a transmembrane region, and a cytoplasmic domain with consensus tyrosine phosphorylation and SH2 binding sites. Transmembrane CXCL16 can serve as a scavenger receptor that binds to oxidized low density lipoprotein, phosphatidylserine, or bacteria and mediates their uptake by macrophages and dendritic cells. Cell surface CXCL16 can be shed in a soluble form after proteolytic cleavage to exert its chemotactic function. CXCL16 is differentially expressed by keratinocytes, monocytes, dendritic cells, endothelial cells, and some activated T cells. CXCL16 exerts its chemotactic function by binding to and signaling through the CXCR6 (CD186) chemokine receptor that is variably expressed by effector/memory CD8+ T cells, CD4+ T cells with Th1- or Th17-like phenotypes, γδ T cells, natural killer (NK) cells, natural killer T (NKT) cells, and monocytes. The 22-19-12 antibody reportedly binds to the chemokine domain of CXCL16 and can inhibit the chemotactic activity of soluble CXCL16.
BD™ CompBeads can be used as surrogates to assess fluorescence spillover (Compensation). When fluorochrome conjugated antibodies are bound to BD CompBeads, they have spectral properties very similar to cells. However, for some fluorochromes there can be small differences in spectral emissions compared to cells, resulting in spillover values that differ when compared to biological controls. It is strongly recommended that when using a reagent for the first time, users compare the spillover on cells and BD CompBead to ensure that BD CompBeads are appropriate for your specific cellular application. For optimal and reproducible results, BD Horizon Brilliant Stain Buffer should be used anytime two or more BD Horizon Brilliant dyes are used in the same experiment. Fluorescent dye interactions may cause staining artifacts which may affect data interpretation. The BD Horizon Brilliant Stain Buffer was designed to minimize these interactions. More information can be found in the Technical Data Sheet of the BD Horizon Brilliant Stain Buffer (Cat. No. 563794/566349) or the BD Horizon Brilliant Stain Buffer Plus (Cat. No. 566385).
Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated to the dye under optimum conditions that minimize unconjugated dye and antibody.
1. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
2. Researchers should determine the optimal concentration of this reagent for their individual applications.
3. An isotype control should be used at the same concentration as the antibody of interest.
4. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
5. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
6. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
7. BD Horizon Brilliant Stain Buffer is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,575,303; 8,354,239.
8. Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
9. Alexa Fluor® is a registered trademark of Life Technologies Corporation.
10. BD Horizon Brilliant Violet 711 is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,227,187; 8,455,613; 8,575,303; 8,354,239.
11. Cy is a trademark of GE Healthcare.
